AstraZeneca divests rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma (Atnahs) to established hypertension medicines

Jan 27, 2020: AstraZeneca has decided to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs).

The agreement excludes the rights in the US and India, which were previously deprived, and in Japan, which will be reserved by AstraZeneca.

These medicines, used primarily to treat hypertension, have lost their patent protection worldwide. AstraZeneca will continue to manufacture and supply to Atnahs during a transition period.

Financial considerations: Atnahs will make an candid payment of $350m to AstraZeneca. AstraZeneca may also be received future sales-contingent payments of up to $40m between 2020 and 2022.

In 2018, Inderal, Tenormin, Tenoretic, Zestril and Zestoretic produced annual sales of $132m in the markets covered by this agreement. 

The divestment is expected to be completed in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.                                                                     

https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-rights-to-established-hypertension-medicines-27012020.html